BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26972631)

  • 1. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study.
    Andersson C; Enserro D; Sullivan L; Wang TJ; Januzzi JL; Benjamin EJ; Vita JA; Hamburg NM; Larson MG; Mitchell GF; Vasan RS
    Atherosclerosis; 2016 May; 248():245-51. PubMed ID: 26972631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of cardiovascular stress and incident chronic kidney disease.
    Ho JE; Hwang SJ; Wollert KC; Larson MG; Cheng S; Kempf T; Vasan RS; Januzzi JL; Wang TJ; Fox CS
    Clin Chem; 2013 Nov; 59(11):1613-20. PubMed ID: 23873716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of cardiovascular stress and subclinical atherosclerosis in the community.
    Gopal DM; Larson MG; Januzzi JL; Cheng S; Ghorbani A; Wollert KC; Kempf T; D'Agostino RB; Polak JF; Ramachandran VS; Wang TJ; Ho JE
    Clin Chem; 2014 Nov; 60(11):1402-8. PubMed ID: 25237063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke.
    Andersson C; Preis SR; Beiser A; DeCarli C; Wollert KC; Wang TJ; Januzzi JL; Vasan RS; Seshadri S
    Stroke; 2015 Sep; 46(9):2568-75. PubMed ID: 26219649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Growth Differentiation Factor 15 with Arterial Stiffness and Endothelial Function in Subpopulations of Patients with Coronary Artery Disease: A Proof-of-Concept Study.
    Mourouzis K; Siasos G; Bozini N; Oikonomou E; Zaromitidou M; Tsigkou V; Kokkou E; Bletsa E; Stampouloglou P; Vavuranakis M; Tousoulis D
    Recent Adv Inflamm Allergy Drug Discov; 2022; 16(2):107-115. PubMed ID: 36336806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
    Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.
    Jia X; Sun W; Hoogeveen RC; Nambi V; Matsushita K; Folsom AR; Heiss G; Couper DJ; Solomon SD; Boerwinkle E; Shah A; Selvin E; de Lemos JA; Ballantyne CM
    Circulation; 2019 Jun; 139(23):2642-2653. PubMed ID: 31030544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation.
    Rienstra M; Yin X; Larson MG; Fontes JD; Magnani JW; McManus DD; McCabe EL; Coglianese EE; Amponsah M; Ho JE; Januzzi JL; Wollert KC; Fradley MG; Vasan RS; Ellinor PT; Wang TJ; Benjamin EJ
    Am Heart J; 2014 Jan; 167(1):109-115.e2. PubMed ID: 24332149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.
    Lichtenauer M; Jirak P; Wernly B; Paar V; Rohm I; Jung C; Schernthaner C; Kraus J; Motloch LJ; Yilmaz A; Hoppe UC; Christian Schulze P; Kretzschmar D; Pistulli R
    Eur J Intern Med; 2017 Oct; 44():31-38. PubMed ID: 28579310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study.
    Bansal N; Zelnick L; Shlipak MG; Anderson A; Christenson R; Deo R; deFilippi C; Feldman H; Lash J; He J; Kusek J; Ky B; Seliger S; Soliman EZ; Go AS;
    Clin Chem; 2019 Nov; 65(11):1448-1457. PubMed ID: 31578216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of subclinical myocardial injury with arterial stiffness in patients with type 2 diabetes mellitus.
    Yiu KH; Zhao CT; Chen Y; Siu CW; Chan YH; Lau KK; Liu S; Lau CP; Tse HF
    Cardiovasc Diabetol; 2013 Jun; 12():94. PubMed ID: 23799879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.
    Gaggin HK; Szymonifka J; Bhardwaj A; Belcher A; De Berardinis B; Motiwala S; Wang TJ; Januzzi JL
    JACC Heart Fail; 2014 Feb; 2(1):65-72. PubMed ID: 24622120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
    Rabkin SW; Tang JKK
    Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Soluble Suppression of Tumorigenesis-2 (ST2) with Endothelial Function in Patients with Ischemic Heart Failure.
    Dimitropoulos S; Mystakidi VC; Oikonomou E; Siasos G; Tsigkou V; Athanasiou D; Gouliopoulos N; Bletsa E; Kalampogias A; Charalambous G; Tsioufis C; Vavuranakis M; Tousoulis D
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy.
    Bidadkosh A; Lambooy SPH; Heerspink HJ; Pena MJ; Henning RH; Buikema H; Deelman LE
    Diabetes Care; 2017 Jun; 40(6):784-792. PubMed ID: 28341782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of circulating growth differentiation factor-15, Krüppel-like factor 4 and growth arrest-specific 6 with coronary artery disease.
    Liu H; Lyu YN; Li D; Cui Y; Dai W; Li Y
    Clin Chim Acta; 2019 Aug; 495():630-636. PubMed ID: 31153870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.
    Stojkovic S; Kaider A; Koller L; Brekalo M; Wojta J; Diedrich A; Demyanets S; Pezawas T
    J Cell Mol Med; 2018 Apr; 22(4):2422-2429. PubMed ID: 29397580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.